Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab in R/M SCCHN
NCT02823574Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Nivolumab + Ipilimumab with Nivolumab + Placebo (2 arms). Primary endpoints: Objective Response Rate at 30 months, Duration of Response at 30 months and 1 more. Started Nov 2016; status: completed.
02
Drugs
ipilimumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02823574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823574.